BPC-157 Research: Gastrointestinal Cell Models and Mucosal Pathway Studies
BPC-157 is a research compound studied in cell-based assay formats for its VEGFR2 receptor pharmacology, FAK/paxillin signalling, and NO synthase pathway interactions. Published in vitro research characterises its molecular interactions, binding affinity profiles, and downstream pathway engagement in defined cell model systems under controlled laboratory conditions.
Receptor Pharmacology and Mechanism of Action
VEGFR2 Signalling Pathway
BPC-157 demonstrates measurable interactions with vascular endothelial growth factor receptor 2 (VEGFR2) in endothelial cell models. Competitive radioligand binding assays reveal specific binding characteristics at this receptor, with functional assays demonstrating downstream tyrosine kinase activation cascades. The compound's engagement with VEGFR2 triggers phosphorylation events that initiate angiogenic signalling pathways, as measured through Western blot analysis of phospho-VEGFR2 expression levels in cultured endothelial cell lines.
Enzyme-linked immunosorbent assays (ELISA) demonstrate concentration-dependent activation of VEGF-mediated signalling cascades, with measurable increases in downstream effector molecules including phospholipase C-gamma and protein kinase B (AKT) phosphorylation states. Time-course studies in human umbilical vein endothelial cell (HUVEC) models show peak receptor activation occurring within 15-30 minutes following compound exposure.
FAK/Paxillin Mechanotransduction
Focal adhesion kinase (FAK) and paxillin represent critical components of cellular mechanotransduction pathways that respond to BPC-157 exposure in gastrointestinal epithelial cell models. Immunofluorescence microscopy reveals enhanced phospho-FAK localization at focal adhesion sites, accompanied by increased paxillin recruitment and phosphorylation.
Cell adhesion assays demonstrate enhanced integrin-mediated attachment following BPC-157 treatment, correlating with increased FAK autophosphorylation at tyrosine 397. This phosphorylation event serves as a docking site for SH2 domain-containing proteins, initiating downstream signalling cascades that influence cellular migration and proliferation parameters in intestinal epithelial cell lines.
Nitric Oxide Synthase Pathway Modulation
eNOS Enzymatic Activity
BPC-157 exhibits modulatory effects on endothelial nitric oxide synthase (eNOS) activity in vascular cell culture systems. Griess reagent assays demonstrate altered nitrite production patterns, indicating changes in NO bioavailability following compound exposure. Enzyme kinetic studies reveal modified Michaelis-Menten parameters for eNOS catalytic activity, suggesting direct or indirect interactions with this critical signalling enzyme.
Calcium mobilization assays in endothelial cell models show altered intracellular calcium dynamics, which directly influence eNOS activation through calmodulin-dependent mechanisms. Fluorometric calcium imaging demonstrates modified calcium transient patterns that correlate with observed changes in NO production.
L-Arginine/NO Pathway
The L-arginine-nitric oxide pathway represents a key target for BPC-157's molecular actions in vascular cell models. Amino acid uptake assays reveal enhanced L-arginine transport in treated cell cultures, potentially contributing to increased substrate availability for NO synthesis. High-performance liquid chromatography (HPLC) analysis confirms elevated L-arginine concentrations in cell lysates following compound exposure.
Gastrointestinal Cell Model Applications
Intestinal Epithelial Barrier Function
In vitro permeability assays using Caco-2 monolayers demonstrate BPC-157's effects on tight junction integrity. Transepithelial electrical resistance (TEER) measurements reveal changes in barrier function parameters, while fluorescein isothiocyanate-dextran (FITC-dextran) permeability assays quantify paracellular transport modifications.
Immunocytochemical analysis of tight junction proteins including claudin-1, occludin, and zonula occludens-1 (ZO-1) shows altered expression patterns and subcellular localization following compound treatment. These molecular changes correlate with observed functional modifications in epithelial barrier properties.
Gastric Cell Line Studies
Primary gastric epithelial cell cultures and immortalized gastric cell lines provide experimental models for investigating BPC-157's gastroprotective mechanisms. Cell viability assays including MTT and LDH release measurements characterize cellular responses under various experimental conditions.
Prostaglandin E2 (PGE2) enzyme immunoassays reveal modified cyclooxygenase pathway activity, while inflammatory mediator multiplex assays demonstrate changes in cytokine production profiles including interleukin-1β, tumor necrosis factor-α, and interleukin-6 expression levels.
Research Summary
BPC-157 demonstrates complex pharmacological properties through its interactions with VEGFR2 signalling, FAK/paxillin mechanotransduction, and nitric oxide synthase pathways in gastrointestinal and vascular cell models. The compound's multi-target approach influences cellular adhesion, barrier function, and vascular signalling mechanisms through measurable receptor-mediated processes. Continued investigation of these molecular pathways in defined cell culture systems provides valuable insights into the compound's fundamental pharmacological properties and potential applications in gastrointestinal research models.
All content is intended for in vitro laboratory research purposes only. Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any condition.
Hexarelin
TB-500
Epithalon
Ipamorelin
Tirzepatide
CJC-1295 DAC
PT-141
Semaglutide
Selank
BPC-157
Sermorelin
Melanotan 2
IGF LR3
Tesamorelin
AICAR
IGF-DES
GHRP 2
Albuterol
Tamoxifen
Letrozole
Clomiphene
Tadalafil
Clenbuterol
Anastrozole
Finasteride
Exemestane
Sildenafil
Yohimbine
Bacteriostatic Water Recent Posts Melanotan 2 (MT2): Mechanism, Research, and Safety Considerations Ipamorelin: The Selective GHRP, Explained Tesamorelin: The GHRH Analog Studied for Visceral Fat Sermorelin: The Original GHRH Analog, Explained CJC-1295: How the GHRH Analog Works, and What Research Shows
Already a customer? Sign In
Create Account
All products on this site are for Research, Development use only. Products are Not for Human consumption of any kind. The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease.
ElementSarms is a chemical supplier. ElementSarms is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act. ElementSarms is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic act.
Sarms
Stacks
Research Liquids
Albuterol 5MG/ML | 30ML with dropper
Anastrozole 1.5MG/ML | 30ML with dropper
Clomiphene 50MG/ML | 30ML with dropper
Finasteride 5MG/ML | 30ML with dropper
Letrozole 3.5 MG/ML | 30ML with dropper
LiquiCia 30MG/ML | 30ML with dropper
LiquiCia T50 50MG/ML | 30ML with dropper
LiquiClen 200MCG/ML | 30ML with dropper
Liquistane / Exemestane 25MG/ML | 30ML with dropper
LiquiTamo 20MG/ML | 30ML with dropper
LiquiVia 25MG/ML | 30 ML with dropper
T3 LIOTHYRONINE 200MCG/ML | 30ML with dropper
Toremifene Citrate 60MG/ML | 30ML with dropper
Yohimbine HCL 10MG/ML | 30ML with dropper
Research Peptides
Aicar 50MG
BPC-157 + TB-500 Blend 2mg ea/ 4MG
BPC-157 5MG
CJC-1295 + DAC 2MG
CJC-1295 | No DAC 2MG
Epithalon 10MG
Frag Premium 176-191 5MG
GHK-CU Copper Peptide 50MG
GHRP-2 5MG
GHRP-6 5MG
Hexarelin 5MG
IGF-1 DES 1MG
IGF-1 LR3 1MG
Ipamorelin 5MG
Melanotan 2 10MG
NAD+ 500MG
PT-141 / Bremelanotide 10MG
GLP-1/GIP/GCG (RT)
Selank 5MG
GLP1 (SM)
Sermorelin 5MG
TB-500 5MG
GIP/GLP-1 (TZ)
PDE5 Inhibitors
GLP-1
Diluents
Bacteriostatic Water 10ML